Literature DB >> 7038093

DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides.

W O Foye, O Vajragupta, S K Sengupta.   

Abstract

The determination of DNA-binding specificities for a series of bis(methylthio)vinylquinolinium iodides and two bis (aminoalkyl)-anthraquinones was accomplished by spectral analysis, equilibrium dialysis, elevation of melting temperature, and inhibition of DNA function as a template for Escherichia coli RNA-polymerase transcription activity in vitro. Studies of complex formation were carried out by comparison of difference spectra of the compounds in the presence of native double-stranded DNA and separated-strand DNA. Base specificity of the interaction between DNA and the compounds was demonstrated for both series, particularly for the anthraquinones, for the guanine-cytosine base pair. Comparison of the difference spectra of the compounds in the presence of DNA with varied base-pair ratios showed a strong preference of the anthraquinones for the guanine-cytosine base pair, but the quinolinium compounds showed no preference. The linear-binding isotherm for the quinolinium compounds indicated one type of binding site, while two types of binding sites were apparent for the anthraquinones. Since only one anthraquinone was active in leukemia tests, factors other than DNA binding must account for the activity of the antileukemic derivative.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7038093     DOI: 10.1002/jps.2600710228

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

2.  DNA sequence specificity of mitoxantrone.

Authors:  C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

3.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

Review 4.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

6.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Development of mitoxantrone.

Authors:  R J White; F E Durr
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.

Authors:  V Heinemann; D Murray; R Walters; R E Meyn; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol.

Authors:  J P Laporte; N C Gorin; M P Lemonnier; F Isnard; A Najman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 10.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.